How to stop hair loss from GLP-1

You are dealing with a symptom and want to know if it is expected.

Reference and calculator, not medical advice. This page explains how something works; it does not tell you what to take. Last reviewed August 2026.

The labels record how often this was reported and how many people stopped treatment because of it. They do not record how to stop it, how long it lasts, or whether it reverses. That is the honest boundary of what the source documents contain, and most pages answering this question are filling that space with something other than evidence.

What each label actually reports

Incidence figures come from the adverse-reaction sections of the prescribing information. The two weight-management products report trial data; the diabetes products list alopecia only as a postmarketing report.

Product	Reported in	Women	Men
Wegovy Semaglutide	Clinical trials	4%	0.9%
Zepbound Tirzepatide	Clinical trials	7.1%	0.5%
Ozempic Semaglutide	Postmarketing reports only	no denominator	no denominator
Mounjaro Tirzepatide	Postmarketing reports only	no denominator	no denominator
Rybelsus Semaglutide (oral)	Postmarketing reports only	no denominator	no denominator
Saxenda Liraglutide	Postmarketing reports only	no denominator	no denominator
Trulicity Dulaglutide	Postmarketing reports only	no denominator	no denominator

A postmarketing entry means the reaction has been reported after approval but the label gives no rate, because spontaneous reports have no denominator. It is not evidence that the rate is lower — only that it was not measured. Every figure above is checked against the label linked at the foot of this page.

The one number that speaks to severity is from the Zepbound trials: no patient taking the drug discontinued because of hair loss, while one patient on placebo did. That is a small dataset and it is not a statement about how distressing people found it — but it is the only published signal about whether this reaction drove people off treatment, and it points one way.

The most productive move is usually not aimed at the medication at all. Thyroid dysfunction, iron deficiency and a number of common drugs all affect hair, are checkable with a blood test, and are correctable in ways this reaction is not. Attributing shedding to the GLP-1 because the timing fits is exactly how a treatable cause goes unexamined for a year.

Common questions

Will it stop on its own?: The labels do not say. They contain no information on duration or resolution for this reaction, in either direction.
Should I stop the medication?: That weighs against why you started, which this page knows nothing about. It is a prescriber conversation, and worth having as a conversation rather than a unilateral stop.
What makes this urgent rather than a wait-and-see?: Patchy rather than diffuse loss, sudden acceleration, or anything alongside other symptoms. Those are different presentations from what the trials recorded and warrant being examined.

Sources and last review

This page is general reference rather than a dosing table, so it quotes no figures from a label. Nothing here is reviewed by a clinician, and this site does not employ one — which is exactly why what I do publish stays traceable to its source.

This page carries no product-specific dosing figures. The labels behind everything on this site are listed on the sources page, and the originals live on DailyMed.

Transcribed from the labels above and checked by me — Gavin, who builds this site, takes a GLP-1, and is not a clinician. Last reviewed August 2026. Found an error? [email protected] — I treat corrections as bugs. How this site is built and funded.

Also searched as: how to stop hair loss from glp-1

How to stop hair loss from GLP-1

Common questions

Sources and last review

Related